ACHIEVE LIFE SCIENCES, INC. — Director's Dealing 2017

Aug 3, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ACHIEVE LIFE SCIENCES, INC. (ACHV)
CIK: 0000949858
Period of Report: 2017-08-01

Reporting Person: PARKER H STEWART (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-08-01	Stock Option (right to buy)	$4.57	A	11000	Acquired	2027-08-01	Common Stock (11000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1136	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$156.20	2020-06-08	Common Stock (67)	67	Direct
Stock Option (right to buy)	$196.02	2021-05-26	Common Stock (318)	318	Direct
Stock Option (right to buy)	$138.16	2022-05-31	Common Stock (363)	363	Direct
Stock Option (right to buy)	$118.03	2023-05-24	Common Stock (454)	454	Direct
Stock Option (right to buy)	$39.82	2024-06-05	Common Stock (454)	454	Direct
Stock Option (right to buy)	$20.79	2025-05-21	Common Stock (454)	454	Direct
Stock Option (right to buy)	$11.00	2026-05-26	Common Stock (2045)	2045	Direct

Footnotes

F1: Reflects the 11-for-1 reverse stock split effected on August 1, 2017 immediately following the merger between OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc.

F2: The options are fully vested and exercisable.